Effect of cimetidine on the pharmacokinetics of oral gemifloxacin in healthy volunteers

Clinical Drug Investigation

Volumn 21, Issue 7, 2001, Pages 519-526

  Allen, A ^a   Bird, N ^a   Dixon, R ^a   Hickmott, F ^a   Pay, V ^a   Smith, A ^a   Stahl, M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; GEMIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0034914050     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121070-00008     Document Type: Article

References (19)

1. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone
2. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
3. International multicenter investigation of LB20304, a new fluoronaphthyridone
4. Comparative in vitro activity of gemifloxacin, moxifloxacin, trovafloxacin, sparfloxacin, grepafloxacin, ofloxacin, ciprofloxacin and other antimicrobial agents against bloodstream isolates of Gram-positive cocci
5. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
6. SB-265805 “LB20304a”: In-vitro activity, intracellular accumulation and killing of Legionella pneumophila in human macrophages [poster F-100]
7. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp.
8. In vitro activity of SB-265805 versus gatifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens
9. Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers
10. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers
11. Quinolones
12. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions
13. Differential inhibition of individual human liver Cytochromes P-450 by cimetidine
14. Effects of cimetidine on the pharmacokinetics of temafloxacin
15. Effects of cimetidine on the pharmacokinetics of pefloxacin
16. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers
17. Rapid determination of gemifloxacin in human plasma by high performance liquid chromatography-tandem mass spectrometry
18. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
19. A distribution free procedure for the statistical analysis of bioequivalence